Fig. 1From: The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosisChronogram of the marketing authorization and the extension of indications of IVA in the US and in the EU. Five extensions of common indications FDA-EMA have been granted by the FDA 5.2 months (1.3–8.1) before the EMA’s approvalBack to article page